New drug targets genetic dementia in small trial

NCT ID NCT03987295

Completed Disease control Sponsor: Alector Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called AL001 in 33 people who carry a gene mutation that causes frontotemporal dementia, a brain disease that affects personality and language. The goal was to see if the drug is safe and how it affects certain proteins in the body. The trial was open-label, meaning everyone knew they were getting the drug, and it focused on safety and biological changes rather than symptom improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AL001 (latozinemab)
What this could lead to: If successful, this could point toward a treatment that slows or stops frontotemporal dementia in people with specific genetic mutations.
What could go wrong: This is an early-phase, small study (33 people) focused on safety and biological markers, not on whether the drug improves symptoms. It may not lead to an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRONTOTEMPORAL DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

frontotemporal dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRONTOTEMPORAL DEMENTIA

Contacts and locations

Locations

Brain Research Center - PPDS

Amsterdam, 1081GN, Netherlands
Erasmus University Medical Center

Rotterdam, 3015 GD, Netherlands
Lawson Health Research Institute, St. Joseph's

London, Ontario, N6A 4V2, Canada
Mayo Clinic

Rochester, Minnesota, 55905, United States
Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada
Technical University of Munich

München, 81675, Germany
The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases UT Health San Antonio

San Antonio, Texas, 78229, United States
UCSF

San Francisco, California, 94158, United States
University College London

London, WC1N 3BG, United Kingdom
University of Brescia

Brescia, 25123, Italy
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Ulm

Ulm, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.